BR112019011070A2 - regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide - Google Patents
regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoideInfo
- Publication number
- BR112019011070A2 BR112019011070A2 BR112019011070-4A BR112019011070A BR112019011070A2 BR 112019011070 A2 BR112019011070 A2 BR 112019011070A2 BR 112019011070 A BR112019011070 A BR 112019011070A BR 112019011070 A2 BR112019011070 A2 BR 112019011070A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- drug
- fracture
- hormone receptor
- parathyroid hormone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428492P | 2016-11-30 | 2016-11-30 | |
| US62/428,492 | 2016-11-30 | ||
| US201762553313P | 2017-09-01 | 2017-09-01 | |
| US62/553,313 | 2017-09-01 | ||
| PCT/US2017/064081 WO2018102616A1 (en) | 2016-11-30 | 2017-11-30 | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019011070A2 true BR112019011070A2 (pt) | 2019-10-01 |
Family
ID=62241919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019011070-4A BR112019011070A2 (pt) | 2016-11-30 | 2017-11-30 | regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20200317745A1 (https=) |
| EP (1) | EP3548012A4 (https=) |
| JP (2) | JP7649624B2 (https=) |
| CN (1) | CN110114065A (https=) |
| AU (1) | AU2017367699B2 (https=) |
| BR (1) | BR112019011070A2 (https=) |
| CA (1) | CA3045458A1 (https=) |
| IL (1) | IL266977B2 (https=) |
| MX (1) | MX2019006189A (https=) |
| WO (1) | WO2018102616A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102616A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| WO2019232285A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| CN110551201B (zh) * | 2019-08-26 | 2020-04-28 | 杭州彗搏科技有限公司 | 一种新型骨形成蛋白2来源的环肽、制备方法及其应用 |
| MX2022002979A (es) * | 2019-09-12 | 2022-06-16 | Radius Health Inc | Metodos para mejorar la fusion vertebral con abaloparatida. |
| CN112646042A (zh) * | 2019-10-10 | 2021-04-13 | 陕西麦科奥特科技有限公司 | 活性多肽化合物 |
| AU2021338361A1 (en) * | 2020-09-03 | 2023-04-06 | Chen, Irvin S.Y | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| WO2022093373A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat bone fractures |
| WO2022093374A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat spinal fusions |
| AU2022205801A1 (en) * | 2021-01-05 | 2023-07-13 | Radius Health, Inc. | Treatment of long bone fractures with abaloparatide |
| US20250295725A1 (en) * | 2022-01-14 | 2025-09-25 | Purdue Research Foundation | Bone targeted treatment in osteogenesis imperfecta |
| EP4719459A1 (en) * | 2023-06-01 | 2026-04-08 | Radius Health, Inc. | Methods for identification and quantitation of abaloparatide and related peptide impurities |
| WO2025019691A1 (en) * | 2023-07-19 | 2025-01-23 | Zymeron Corporation | Drug conjugates for bone marrow protection |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9103791A (en) * | 1990-12-21 | 1992-07-22 | Allelix Biopharmaceuticals Inc. | Oxidation resistant variants of parathyroid hormone |
| WO1995002610A1 (en) * | 1993-07-13 | 1995-01-26 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| JP4394279B2 (ja) * | 1998-03-09 | 2010-01-06 | ジーランド ファーマ アクティーゼルスカブ | 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体 |
| US7057012B1 (en) * | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| JP2000327583A (ja) | 1999-05-17 | 2000-11-28 | Medei Sci Puraningu:Kk | 骨指向性ホルモン誘導体 |
| WO2004062588A2 (en) * | 2003-01-06 | 2004-07-29 | University Of Utah | Water-soluble polymeric bone-targeting drug delivery system |
| DE602005027461D1 (de) | 2004-04-21 | 2011-05-26 | Enobia Pharma Inc | Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen |
| US7863238B2 (en) | 2004-06-10 | 2011-01-04 | Saint Louis University | Proteins with an attached short peptide of acidic amino acids |
| US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
| KR101512377B1 (ko) | 2006-10-03 | 2015-04-28 | 라디우스 헬쓰, 인코포레이티드 | 골 아나볼릭 단백질을 위한 약물 전달 방법 |
| US7803770B2 (en) * | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| WO2008124166A2 (en) | 2007-04-09 | 2008-10-16 | The Board Of Trustees Of The University Of Arkansas | Fusion proteins of collagen-binding domain and parathyroid hormone |
| PT2662448T (pt) | 2007-05-11 | 2017-03-29 | Alexion Pharma Inc | Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma |
| EP2303288A4 (en) * | 2008-05-22 | 2015-04-22 | Univ Ramot | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESE MEDIUM AND ITS USE IN THE TREATMENT AND CONTROL OF ILLNESSES RELATED TO BONE |
| WO2012111852A1 (ja) * | 2011-02-17 | 2012-08-23 | 帝人ファーマ株式会社 | 椎体骨折治療剤及びその評価方法 |
| BR112013027153A2 (pt) | 2011-04-22 | 2016-11-29 | 3M Innovative Properties Co | método de aplicação de fármaco para pth, pthrp e peptídeos relacionados |
| CN102824647B (zh) * | 2011-06-13 | 2014-07-23 | 香港中文大学 | 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法 |
| CA2883707A1 (en) * | 2012-08-28 | 2014-03-06 | The Governors Of The University Of Alberta | Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof |
| WO2014209893A2 (en) | 2013-06-23 | 2014-12-31 | Wisconsin Alumni Research Foundation | Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same |
| CA2977812A1 (en) * | 2015-03-03 | 2016-09-09 | Radius Health, Inc. | Uses of pthrp analogue in reducing fracture risk |
| WO2016196400A1 (en) * | 2015-05-29 | 2016-12-08 | Purdue Research Foundation | Bone fracture repair by targeting of agents that promote bone healing |
| CN106039316B (zh) * | 2016-05-03 | 2019-04-02 | 同济大学 | 一种基于多肽构建的成骨细胞靶向载体及其制备与应用 |
| WO2018102616A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| WO2022093373A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat bone fractures |
-
2017
- 2017-11-30 WO PCT/US2017/064081 patent/WO2018102616A1/en not_active Ceased
- 2017-11-30 CA CA3045458A patent/CA3045458A1/en active Pending
- 2017-11-30 JP JP2019529240A patent/JP7649624B2/ja active Active
- 2017-11-30 CN CN201780073942.4A patent/CN110114065A/zh active Pending
- 2017-11-30 IL IL266977A patent/IL266977B2/en unknown
- 2017-11-30 BR BR112019011070-4A patent/BR112019011070A2/pt active Search and Examination
- 2017-11-30 EP EP17875427.1A patent/EP3548012A4/en active Pending
- 2017-11-30 MX MX2019006189A patent/MX2019006189A/es unknown
- 2017-11-30 US US16/464,164 patent/US20200317745A1/en not_active Abandoned
- 2017-11-30 AU AU2017367699A patent/AU2017367699B2/en active Active
-
2020
- 2020-03-31 US US16/836,366 patent/US10960054B2/en active Active
-
2021
- 2021-02-24 US US17/184,400 patent/US20210283227A1/en active Pending
-
2022
- 2022-12-02 JP JP2022193738A patent/JP2023029957A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023029957A (ja) | 2023-03-07 |
| IL266977B1 (en) | 2023-09-01 |
| AU2017367699B2 (en) | 2023-12-07 |
| WO2018102616A1 (en) | 2018-06-07 |
| AU2017367699A8 (en) | 2019-07-25 |
| US10960054B2 (en) | 2021-03-30 |
| IL266977B2 (en) | 2024-01-01 |
| MX2019006189A (es) | 2019-11-18 |
| AU2017367699A1 (en) | 2019-07-11 |
| EP3548012A1 (en) | 2019-10-09 |
| JP2020500871A (ja) | 2020-01-16 |
| RU2019119701A3 (https=) | 2021-02-16 |
| CA3045458A1 (en) | 2018-06-07 |
| US20200317745A1 (en) | 2020-10-08 |
| CN110114065A (zh) | 2019-08-09 |
| US20210283227A1 (en) | 2021-09-16 |
| IL266977A (en) | 2019-07-31 |
| RU2019119701A (ru) | 2021-01-14 |
| EP3548012A4 (en) | 2020-07-22 |
| US20200316174A1 (en) | 2020-10-08 |
| JP7649624B2 (ja) | 2025-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019011070A2 (pt) | regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide | |
| BR112016016290A2 (pt) | Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina | |
| BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
| BR112015022274A2 (pt) | sistema e método de substituição de tornozelo | |
| CL2019000266A1 (es) | Composición de cannabis. | |
| CL2018001007A1 (es) | Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538). | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| MX2017015599A (es) | Dispositivo de administracion de farmacos con resorte indicador audible. | |
| MX2015000990A (es) | Analogos del glucagon. | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| BR112015012739A2 (pt) | sistemas e métodos de guia ortopédico | |
| BR112016002646A2 (pt) | dispositivos e métodos de entrega de fármaco de múltiplas unidades | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| HK1255593A1 (zh) | 具有柱塞杆剂量控制机构的注射器 | |
| BR112014031372A2 (pt) | implantes/procedimentos relacionados ao avanço da tuberosidade tibial | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| BR112021018456A2 (pt) | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento | |
| BR112017015285A2 (pt) | dispositivo de fixação transcraniano para pelo menos um cateter de drenagem | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| CL2020000170A1 (es) | Composición para su uso en la prevención y el tratamiento de patologías del aparato cardiovascular. | |
| BR112015024464A2 (pt) | dispositivo de infusão com estrutura em camadas tendo componentes duráveis e descartáveis | |
| BR112017000312A2 (pt) | sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal | |
| BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo | |
| FR3053239B1 (fr) | Susbtitut osseux et systeme d'injection autonome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |